24 September 2019 in Journal of Neuro-Oncology
18 August 2023 in Neuro-Oncology
Background: Given the invasive nature of glioblastoma, tumor cells exist beyond the contrast-enhancing (CE) region targeted during treatment. However, areas of non-enhancing (NE) tumors are difficult to visualize and delineate from edematous tissue. Amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) is a pH-sensitive molecular magnetic resonance imaging technique that was evaluated in its ability to identify infiltrating NE tumors and prognosticate survival. Methods: In this prospective study, CEST-EPI was obtained in 30 patients and areas with elevated CEST contrast (“CEST+” based on the asymmetry in magnetization transfer ratio: MTRasym at 3 ppm) within NE regions were quantitated. Median MTRasym at 3 ppm and volume of CEST + NE regions were correlated with progression-free survival (PFS). In 20 samples from 14 patients, image-guided biopsies of these areas were obtained to correlate MTRasym at 3 ppm to tumor and non-tumor cell burden using immunohistochemistry. Results: In 15 newly diagnosed and 15 recurrent glioblastoma, higher median MTRasym at 3ppm within CEST + NE regions (P = .007; P = .0326) and higher volumes of CEST + NE tumor (P = .020; P < .001) were associated with decreased PFS. CE recurrence occurred in areas of preoperative CEST + NE regions in 95.4% of patients. MTRasym at 3 ppm was correlated with presence of tumor, cell density, %Ki-67 positivity, and %CD31 positivity (P = .001; P < .001; P < .001; P = .001). Conclusions: pH-weighted amine CEST-EPI allows for visualization of NE tumor, likely through surrounding acidification of the tumor microenvironment. The magnitude and volume of CEST + NE tumor correlates with tumor cell density, degree of proliferating or “active” tumor, and PFS.
1 January 2024 in Neuro-Oncology Advances
Non-enhancing (NE) infiltrating tumor cells beyond the contrast-enhancing (CE) bulk of tumor are potential propagators of recurrence after gross total resection of high-grade glioma. We leveraged single-nucleus RNA sequencing on 15 specimens from recurrent high-grade gliomas (n = 5) to compare prospectively identified biopsy specimens acquired from CE and NE regions. Additionally, 24 CE and 22 NE biopsies had immunohistochemical staining to validate RNA findings. Tumor cells in NE regions are enriched in neural progenitor cell-like cellular states, while CE regions are enriched in mesenchymal-like states. NE glioma cells have similar proportions of proliferative and putative glioma stem cells relative to CE regions, without significant differences in % Ki-67 staining. Tumor cells in NE regions exhibit upregulation of genes previously associated with lower grade gliomas. Our findings in recurrent GBM paralleled some of the findings in a re-analysis of a dataset from primary GBM. Cell-, gene-, and pathway-level analyses of the tumor microenvironment in the NE region reveal relative downregulation of tumor-mediated neovascularization and cell-mediated immune response, but increased glioma-to-nonpathological cell interactions. This comprehensive analysis illustrates differing tumor and nontumor landscapes of CE and NE regions in high-grade gliomas, highlighting the NE region as an area harboring likely initiators of recurrence in a pro-tumor microenvironment and identifying possible targets for future design of NE-specific adjuvant therapy. These findings also support the aggressive approach to resection of tumor-bearing NE regions.
21 December 2020 in Interdisciplinary Neurosurgery
Introduction: Cortical screws offer a less invasive alternative compared to traditional pedicle screws. These screws are inserted in an inferomedial to superolateral trajectory achieving greater cortical bone purchase. Similar fusion rates, pain relief, and decreased surgical morbidity at 12-month follow-up have been documented when compared to traditional pedicle screws. Using intra-operative imaging, neuronavigation, and individual neurophysiological monitoring of each screw, we showed that this is a safe surgical approach. Methods: Institutional review board (IRB) approved retrospective review of medical records for 173 patients to determine eligibility. Cases had to be elective one-or two-level fusion with surgical indication. Functional improvement was measured with Oswestry Disability Index (ODI) at pre and post-operative visits. Surgical morbidity data, individual screw thresholds, and radiographic evidence of stability was collected from electronic medical records (EMR). Results: A total of 153 patients met criteria with mean age 66.60 ± 9.30 (range: 34–84) and mean BMI of 28.76 ± 4.47 kg/m2. Of 558 screws inserted, no screws recorded <8 mA upon stimulation, thus no screw required repositioning. There were no pedicle or central canal breach related to screw insertion. ODI decreased from 44.83 ± 18.02 to 19.46 ± 19.52 at 3-months post-operative (p < 0.0001). A subset of 30 patients had 12-month post ODI, which showed a change from 41.22 ± 18.42 to 22.63 ± 22.01 at 12-months (p < 0.001). Conclusions: Within, we discuss our approach for inserting cortical screws in posterior lumbar fusion for patients with unstable degenerative lumbar spondylolisthesis. Our study shows that the implementation of intraoperative imaging, neuronavigation, and neurophysiological monitoring of individual screws can provide a safe environment for cortical screw insertion. This approach allows for a less invasive approach and greater quality bone purchase while mitigating the associated risks.
1 January 2020 in Neuro-Oncology Advances
Anti-angiogenic therapy with bevacizumab has failed to provide substantial gains in overall survival. Epithelial membrane protein 2 (EMP2) is a cell surface protein that has been previously shown to be expressed in glioblastoma, correlate with poor survival, and regulate neoangiogenesis in cell lines. Thus, the relationship of bevacizumab and EMP2 was investigated. Tumor samples were obtained from 12 patients with newly diagnosed glioblastoma at two time points: 1) during the initial surgery and 2) during a subsequent surgery following disease recurrence post bevacizumab treatment. Clinical characteristics and survival data from these patients were collected, and tumor samples were stained for EMP2 expression. The IVY glioblastoma atlas project database was used to evaluate EMP2 expression levels in 270 samples by differing histological areas of tumor. Patients with high EMP2 staining at initial diagnosis had decreased progression free and overall survival after bevacizumab [median progression free survival 4.6 months vs. 5.9 months; Log-Rank P = 0.076 & overall survival 7.7 months vs. 14.4 months; Log-Rank P = 0.011]. There was increased EMP2 staining in samples obtained after bevacizumab treatment in both unpaired [Mean H-score 2.31 vs 1.76; P=0.006] and paired analyses [Mean difference 0.571; P=0.019]. This expression increase correlated with length of bevacizumab therapy [R2=0.449; Pearson P=0.024]. Bevacizumab treatment increased EMP2 protein expression. This increase in EMP2 correlated with reduced mean survival time post bevacizumab therapy. We hypothesize a role of EMP2 in clinical bevacizumab resistance and as a potential anti-angiogenic therapeutic target in glioblastoma.